X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-09-13 | YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | S - Sale | $13.31 | -95,000 | 286,381 | -25% | -$1,264,650 | |||||
| D | 2024-08-28 | YMAB | Lund-Hansen Torben | SVP, CHIEF TECHNICAL OFFICER | S - Sale+OE | $15.37 | -50,000 | 81,262 | -38% | -$768,500 | |||||
2024-08-26 | YMAB | Wilms Joris | SVP, COO | S - Sale | $14.69 | -5,000 | 30,600 | -14% | -$73,450 | ||||||
2024-06-10 | YMAB | Ber Gerard | Dir | S - Sale | $12.00 | -722 | 1,608 | -31% | -$8,664 | ||||||
| M | 2024-06-10 | YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | S - Sale | $12.02 | -70,000 | 381,381 | -16% | -$841,050 | |||||
| DM | 2024-05-30 | YMAB | Kruse Bo | EVP, CFO, SECRY, TREAS. | S - Sale+OE | $12.05 | -60,000 | 210,877 | -22% | -$723,055 | |||||
| M | 2024-05-21 | YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | S - Sale | $12.23 | -32,351 | 451,381 | -7% | -$395,563 | |||||
2024-03-05 | YMAB | Rajah Vignesh | SVP, CHIEF MEDICAL OFFICER | S - Sale | $16.53 | -1,711 | 38,155 | -4% | -$28,283 | ||||||
2024-03-05 | YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | S - Sale | $16.44 | -3,900 | 483,732 | -1% | -$64,116 | ||||||
2024-03-05 | YMAB | Smith Susan Laura | SVP, CHIEF COMMERCIAL OFFICER | S - Sale | $16.55 | -1,682 | 33,918 | -5% | -$27,837 | ||||||
| M | 2023-12-13 | YMAB | Gad Thomas | Chief Business Officer | S - Sale | $6.67 | -150,000 | 415,532 | -27% | -$1,001,000 | |||||
2023-12-11 | YMAB | Wg Biotech Aps | Dir | P - Purchase | $6.85 | +6,455 | 4,559,233 | 0% | +$44,232 | ||||||
2023-12-11 | YMAB | Wedell-Wedellsborg Johan | Dir | P - Purchase | $6.85 | +6,455 | 4,559,233 | 0% | +$44,232 | ||||||
| M | 2023-12-07 | YMAB | Wg Biotech Aps | Dir | P - Purchase | $6.98 | +127,549 | 4,552,778 | +3% | +$890,411 | |||||
| M | 2023-12-07 | YMAB | Wedell-Wedellsborg Johan | Dir | P - Purchase | $6.98 | +127,549 | 4,552,778 | +3% | +$890,411 | |||||
2023-11-29 | YMAB | Wg Biotech Aps | Dir | P - Purchase | $5.97 | +51,837 | 4,425,229 | +1% | +$309,477 | ||||||
2023-11-29 | YMAB | Wedell-Wedellsborg Johan | Dir | P - Purchase | $5.97 | +51,837 | 4,425,229 | +1% | +$309,477 | ||||||
| M | 2023-11-27 | YMAB | Wedell-Wedellsborg Johan | Dir | P - Purchase | $5.59 | +93,187 | 4,373,392 | +2% | +$521,294 | |||||
| M | 2023-11-27 | YMAB | Wg Biotech Aps | Dir | P - Purchase | $5.59 | +93,187 | 4,373,392 | +2% | +$521,294 | |||||
| M | 2023-11-20 | YMAB | Gad Thomas | Chief Business Officer | S - Sale | $5.30 | -150,000 | 565,532 | -21% | -$795,383 | |||||
2023-05-15 | YMAB | Wedell-Wedellsborg Johan | Dir | P - Purchase | $9.65 | +101,740 | 4,280,205 | +2% | +$981,404 | ||||||
2023-05-15 | YMAB | Wg Biotech Aps | See Remarks | P - Purchase | $9.65 | +101,740 | 4,280,205 | +2% | +$981,404 | ||||||
2022-11-15 | YMAB | Rajah Vignesh | SVP, CMO | P - Purchase | $4.92 | +1,195 | 4,266 | +39% | +$5,884 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |